Why Biotech ETFs are Rising

Increasing M&A deals and cutting edge therapies are driving biotech ETFs higher.

IShares Nasdaq Biotechnology ETF: https://www.zacks.com/funds/etf/IBB/profile?cid=CS-YOUTUBE-FT-VID
SPDR S&P Biotech ETF: https://www.zacks.com/funds/etf/XBI/profile?cid=CS-YOUTUBE-FT-VID
ARK Genomic Revolution ETF: https://www.zacks.com/funds/etf/ARKG/profile?cid=CS-YOUTUBE-FT-VID
Virtus LifeSci Biotech Clinical Trials ETF: https://www.zacks.com/funds/etf/BBC/profile?cid=CS-YOUTUBE-FT-VID
ALPS Medical Breakthroughs ETF: https://www.zacks.com/funds/etf/SBIO/profile?cid=CS-YOUTUBE-FT-VID
Merck: https://www.zacks.com/stock/quote/MRK?cid=CS-YOUTUBE-FT-VID
Biogen: https://www.zacks.com/stock/quote/BIIB?cid=CS-YOUTUBE-FT-VID
Sanofi: https://www.zacks.com/stock/quote/SNY?cid=CS-YOUTUBE-FT-VID
ArQule: https://www.zacks.com/stock/quote/ARQL?cid=CS-YOUTUBE-FT-VID
Synthorx: https://www.zacks.com/stock/quote/THOR?cid=CS-YOUTUBE-FT-VID

Follow us on StockTwits: http://stocktwits.com/ZacksResearch
Follow us on Twitter: https://twitter.com/ZacksResearch
Like us on Facebook: https://www.facebook.com/ZacksInvestmentResearch

Products You May Like

Articles You May Like

New York State’s fiscal 2024 budget hits $227 billion as reserves stay high
Board threatens 0.21% payment for PREPA bondholders who don’t settle
Mortgage demand took a big step back last week, even after interest rates fell further
The ‘Invisible House’ In Joshua Tree, California Lists For $18 Million
POB issuance plunge expected to continue

Leave a Reply

Your email address will not be published. Required fields are marked *